ClinicalTrials.gg
Not yet recruitingNCT07726966Updated Jul 27, 2026

Betacyanin for Early Diagnosis and Recovery of Anastomotic Leakage After Rectal Cancer Surgery: A Single-Center, Prospective, Controlled Trial

An interventional study of Betacyanin and Pelvic Drainage Fluid Betacyanin Assay in Rectum Cancer and Anastomotic Leak, sponsored by Southwest Hospital, China. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Southwest Hospital, China · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This single-center, prospective, controlled trial compares betacyanin versus conventional methods for early diagnosis and healing assessment of anastomotic leakage after rectal cancer surgery.

02

Conditions studied

  • Rectum Cancer
  • Anastomotic Leak

Keywords

  • Early diagnosis
  • Healing evaluation
03

In context

Rectal Neoplasms

2,400 studies on the registry are indexed under Rectal Neoplasms; 587 are open to participants now.

This study's planned enrollment of 120 is above the median of 65 across 1,751 interventional studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

Southwest Hospital, China is the lead sponsor of 87 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed rectal adenocarcinoma prior to surgery.
  2. Undergoing laparoscopic anterior resection for rectal cancer.
  3. No prophylactic diverting ileostomy.
  4. (ASA) Physical Status Classification ≤ 3.
  5. No prior history of malignant tumors, and no evidence of other on preoperative examination.
  6. Written obtained from the patient or a legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Prior abdominal surgery with severe intra-abdominal adhesions.
  2. Currently participating in, or having participated within the past 6 months in, another clinical study related to rectal cancer surgery.
  3. Preoperative complications requiring emergency surgery, including bleeding, perforation, or obstruction.
  4. History of prior .
  5. Undergoing Parks procedure with anastomosis at the anal verge, or Miles procedure, or Hartmann's procedure.
  6. Preoperative chemoradiotherapy, or presence of other high-risk factors for anastomotic leakage requiring a prophylactic diverting ileostomy.
  7. ASA Physical Status Classification > 3.
  8. Patient withdrawal of consent.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Betacyanin + Conventional Monitoring

    All eligible patients who undergo rectal cancer resection will receive the same intervention and monitoring protocol. Starting from postoperative day 3, each patient will orally consume 200 mL of betacyanin solution daily (concentration and formulation as specified in the study protocol). Concurrently, pelvic drainage fluid will be collected daily to measure betacyanin concentration as a potential biomarker for early detection of anastomotic leakage. In parallel, conventional diagnostic methods for anastomotic leakage-including clinical symptom assessment, routine laboratory tests (e.g., white blood cell count, C-reactive protein), and imaging studies when clinically indicated-will be performed on the same patients at the same time points. Thus, each patient serves as his/her own control, allowing a direct comparison of diagnostic accuracy and healing evaluation between betacyanin-based monitoring and conventional approaches. The intervention and monitoring will continue daily until h

    Dietary Supplement: Betacyanin · Diagnostic Test: Pelvic Drainage Fluid Betacyanin Assay

Interventions

  • Dietary supplementBetacyanin

    200 mL oral betacyanin solution administered daily from postoperative day 3 until discharge or confirmation of anastomotic leakage

  • Diagnostic testPelvic Drainage Fluid Betacyanin Assay

    Daily measurement of betacyanin concentration in pelvic drainage fluid for early detection of anastomotic leakage

06

What researchers measure

Primary outcomes

  1. Time to Diagnosis of Anastomotic Leakage

    Time frame: Within 30 days after surgery

Secondary outcomes

  1. Diagnostic Performance of Betacyanin for Anastomotic Leakage

    Time frame: Within 30 days after surgery

  2. Time to Healing of Anastomotic Leakage

    Time frame: Within 30 days after surgery

  3. Incidence of Postoperative Grade III-IV Complications

    Time frame: Within 30 days after surgery

  4. Reoperation Rate

    Time frame: Within 30 days after surgery

  5. Length of Postoperative Hospital Stay

    Time frame: From surgery to hospital discharge, assessed up to 30 days

  6. 30-Day Readmission Rate

    Time frame: Within 30 days after hospital discharge

  7. Cost of Anastomotic Leakage Diagnosis

    Time frame: During index hospitalization, assessed up to 30 days

  8. Total Hospitalization Cost

    Time frame: During index hospitalization, assessed up to 30 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07726966
Lead sponsor
Southwest Hospital, China
Responsible party
Tang Bo (Principal Investigator, Southwest Hospital, China) — Principal investigator
First posted
Jul 27, 2026
Start date
Aug 20, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Bo Tang, MD
Contact
2211934029@qq.com
+8613883902288
Qi Zhang
Contact
502384305@qq.com
+8613508876528

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion